Literature DB >> 21689675

Diltiazem potentiates pentobarbital-induced hypnosis via 5-HT1A and 5-HT2A/2C receptors: role for dorsal raphe nucleus.

Su-Ying Cui1, Xiang-Yu Cui, Juan Zhang, Zi-Jun Wang, Bin Yu, Zhao-Fu Sheng, Xue-Qiong Zhang, Xiao-Lei Shi, Yong-He Zhang.   

Abstract

It has been reported that the sedative component of pentobarbital is mediated by GABA receptors in an endogenous sleep pathway and the ventrolateral preoptic area (VLPO)-tuberomammillary nucleus (TMN) or VLPO-dorsal raphe nucleus (DRN) neural circuit is important in the sedative response to pentobarbital. Our previous findings indicated that the VLPO-TMN neuronal circuit may play crucial part in the augmentative effect of diltiazem on pentobarbital sleep and the serotonergic system may be involved. This study was designed to investigate the role of DRN and the serotonergic receptors 5-HT(1A) and 5-HT(2A/2C) in the augmentative effect of diltiazem on pentobarbital-induced hypnosis in rats. The results showed that diltiazem (5mg/kg, i.g.) significantly reversed pentobarbital-induced (35 mg/kg, i.p.) reduction of c-Fos expression in 5-HT neurons of DRNV (at -7.5mm Bregma), DRND, DRNVL and MRN (at -8.0mm Bregma). However it did not influence this reducing effect of pentobarbital on non-5-HT neurons either in DRN or in MRN. Moreover, the effect of diltiazem (1 or 2mg/kg, i.g.) on pentobarbital-induced (35 mg/kg, i.p.) hypnosis was significantly inhibited by 5-HT(1A) agonist 8-OH-DPAT (0.5mg/kg, i.p.) and 5-HT(2A/2C) agonist DOI (0.5mg/kg, i.p.), and potentiated by 5-HT(1A) antagonist p-MPPI (2mg/kg, i.p.) and 5-HT(2A/2C) antagonist ritanserin (2mg/kg, i.p.), respectively. From these results, it should be presumed that the augmentative effect of diltiazem on pentobarbital-induced sleep may be related to 5-HT(1A) and 5-HT(2A/2C) receptors, and DRN may be involved. In addition, it also suggested that the DRN may play a multi-modulating role in sleep-wake regulation rather than being recognized simply as arousal nuclei.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689675     DOI: 10.1016/j.pbb.2011.06.001

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Glucocorticoid receptors in the locus coeruleus mediate sleep disorders caused by repeated corticosterone treatment.

Authors:  Zi-Jun Wang; Xue-Qiong Zhang; Xiang-Yu Cui; Su-Ying Cui; Bin Yu; Zhao-Fu Sheng; Sheng-Jie Li; Qing Cao; Yuan-Li Huang; Ya-Ping Xu; Yong-He Zhang
Journal:  Sci Rep       Date:  2015-03-24       Impact factor: 4.379

2.  Mechanisms Underlying the Action of Ziziphi Spinosae Semen in the Treatment of Insomnia: A Study Involving Network Pharmacology and Experimental Validation.

Authors:  Zhenhua Bian; Wenming Zhang; Jingyue Tang; Qianqian Fei; Minmin Hu; Xiaowei Chen; Lianlin Su; Chenghao Fei; Chunqin Mao; Huangjin Tong; Xiaohang Yuan; Tulin Lu
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

3.  Ca(2+) in the dorsal raphe nucleus promotes wakefulness via endogenous sleep-wake regulating pathway in the rats.

Authors:  Su-Ying Cui; Sheng-Jie Li; Xiang-Yu Cui; Xue-Qiong Zhang; Bin Yu; Yuan-Li Huang; Qing Cao; Ya-Ping Xu; Guang Yang; Hui Ding; Jin-Zhi Song; Hui Ye; Zhao-Fu Sheng; Zi-Jun Wang; Yong-He Zhang
Journal:  Mol Brain       Date:  2016-07-26       Impact factor: 4.041

4.  Utilizing network pharmacology and experimental validation to explore the potential molecular mechanisms of BanXia-YiYiRen in treating insomnia.

Authors:  Liang Wang; Peng Wang; Yingfan Chen; Chen Li; Xuelin Wang; Yin Zhang; Shaodan Li; Minghui Yang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.